Latest News on Natco Pharma
Showing of 0 - 10 from 12 results
Natco Pharma - Total results - 12
Oct 04, 2017
Natco Pharma zooms 20% as partner's injection gets USFDA nodUS Food and Drug Administration granted approval to the Natco Pharma's marketing partner Mylan's injection used for treatment of relapsing forms of multiple sclerosis
May 10, 2017
Natco Pharma launches blood cancer drug priced Rs 5,000-20,000, down 98% from US priceNatco has priced its generic medicine 1 mg, 2 mg, and 4 mg capsules at Rs 5,000, Rs 10,000 Rs 20,000 respectively for a monthly pack of 21 capsules.
Jan 25, 2017
Natco Pharma's Telangana facility faces 6 observations from US drug regulatorIn August last year, Natco had received Establishment Inspection Report (EIR) for the same facility from the US health regulator after successful completion of inspection
Sep 16, 2016
Natco Pharma to file over 10 ANDAs in US in next 2 fiscalsAs of March 31, 2016, the company has a portfolio of 38 niche ANDA filings in the US, including 16 Para IV filings
Aug 25, 2016
Natco Pharma says USFDA clears inspection of its chemical division unit in ChennaiThe USFDA released a copy of the EIR to the establishment that was the subject of an FDA or FDA-contracted inspection when the agency determines the inspection to be closed
Aug 09, 2016
Natco Pharma Apr-Jun quarter net jumps 70% to Rs 47.65 crIts consolidated net sales were up 38.02 percent to Rs 297.71 crore during the period under review
May 24, 2016
Pharma battle: Indian Patent office and MNCs should resist from the confrontational policyDrug MNCs especially from the US have had a problematic relationship with the Indian Patent office so much so that the US government has placed India in the list of patently unfriendly patent countries in the world
Dec 14, 2015
Natco Pharma, partner clear patent case with Gilead, others over TamifluIn March last year, USFDA had granted tentative approval to Natco for the generic oseltamivir phosphate capsules
Feb 10, 2015
Natco Pharma gains 4.5% after filing ANDA with USFDANatco Pharma has filed new product applications with the US health regulator for generic version of drugs used in the treatment of nervous system disease and cancer.
Jan 16, 2015
Gilead to challenge hepatitis C drug patent rejectionAn order by deputy controller of patents and designs Hardev Karar has said Gilead, which sells the drug under the Sovaldi brand in the US, failed to prove that there were enhancement of therapeutic efficacy in the new discovery.